ID: h-81fc2e051f
Hypothesis
Mitochondrial Quality Control Failure
Impaired mitochondrial dynamics and reduced mitophagy represent a shared energy crisis converging on synaptic vulnerability.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 4 support✗ 3 oppose
✓ All Quality Gates Passed
🧪 Overview
Impaired mitochondrial dynamics and reduced mitophagy represent a shared energy crisis converging on synaptic vulnerability. NAD+ supplementation has tolerable safety profile and pilot data (NADPARK Phase 1) shows brain NAD increase in PD. However, PINK1/Parkin mutations cause PD-specific familial disease, not AD/ALS/FTD, and mitochondrial dysfunction is a final common pathway in normal aging—lacking disease specificity. Best positioned as an adjunctive metabolic intervention in biomarker-enriched subgroups.
🧬 Mechanism
🔗 Mechanism from KG for PINK1, PARK2, MFN2, SIRT3
Auto-built from this analysis's top knowledge-graph edges.
graph TD
GBA1_mutations["GBA1 mutations"] -->|increases risk| PD["PD"]
TREM2_R47H_variant["TREM2 R47H variant"] -->|increases risk| Ad["Ad"]
alpha_synuclein_fibrils["alpha-synuclein fibrils"] -->|activates| NLRP3_Inflammasome["NLRP3 Inflammasome"]
TFEB_overexpression["TFEB overexpression"] -.->|inhibits| tau_A__pathology["tau/Aβ pathology"]
TARDBP_MUTATIONS["TARDBP MUTATIONS"] -->|causes| ALS_FTD["ALS/FTD"]
TDP_43_INCLUSIONS["TDP-43 INCLUSIONS"] -->|associated with| ALS_FTD_1["ALS/FTD"]
NfL_reduction["NfL reduction"] -->|biomarker for| als["als"]
TARDBP["TARDBP"] -->|cross disease mech| ALS["ALS"]
TARDBP_2["TARDBP"] -->|cross disease mech| FTD["FTD"]
TARDBP_3["TARDBP"] -->|cross disease mech| AD_LATE["AD/LATE"]
h_cross_synth_tdp43_rna_p["h-cross-synth-tdp43-rna-proteostasis"] -->|proposes shared me| TARDBP_4["TARDBP"]
SNCA["SNCA"] -->|cross disease mech| PD_5["PD"]
style GBA1_mutations fill:#ce93d8,stroke:#333,color:#000
style PD fill:#ef5350,stroke:#333,color:#000
style TREM2_R47H_variant fill:#ce93d8,stroke:#333,color:#000
style Ad fill:#ef5350,stroke:#333,color:#000
style alpha_synuclein_fibrils fill:#4fc3f7,stroke:#333,color:#000
style NLRP3_Inflammasome fill:#ce93d8,stroke:#333,color:#000
style TFEB_overexpression fill:#4fc3f7,stroke:#333,color:#000
style tau_A__pathology fill:#4fc3f7,stroke:#333,color:#000
style TARDBP_MUTATIONS fill:#ce93d8,stroke:#333,color:#000
style ALS_FTD fill:#ef5350,stroke:#333,color:#000
style TDP_43_INCLUSIONS fill:#4fc3f7,stroke:#333,color:#000
style ALS_FTD_1 fill:#ef5350,stroke:#333,color:#000
style NfL_reduction fill:#ce93d8,stroke:#333,color:#000
style als fill:#ef5350,stroke:#333,color:#000
style TARDBP fill:#4fc3f7,stroke:#333,color:#000
style ALS fill:#ef5350,stroke:#333,color:#000
style TARDBP_2 fill:#4fc3f7,stroke:#333,color:#000
style FTD fill:#ef5350,stroke:#333,color:#000
style TARDBP_3 fill:#4fc3f7,stroke:#333,color:#000
style AD_LATE fill:#ef5350,stroke:#333,color:#000
style h_cross_synth_tdp43_rna_p fill:#4fc3f7,stroke:#333,color:#000
style TARDBP_4 fill:#4fc3f7,stroke:#333,color:#000
style SNCA fill:#4fc3f7,stroke:#333,color:#000
style PD_5 fill:#ef5350,stroke:#333,color:#000⚖️ Evidence
⚖️ Evidence Matrix4 supports3 contradicts
Supports
PINK1/PARKIN mutations cause early-onset familial PD with mitochondrial dysfunction
Supports
NAD+ levels reduced across NDD models; NR supplementation improves outcomes in ALS, AD, and PD models
Supports
NADPARK Phase 1: oral nicotinamide riboside increased brain NAD safely in PD
Contradicts
Mitochondrial dysfunction is observed in virtually all chronic conditions and normal aging
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — PINK1
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for PINK1, PARK2, MFN2, SIRT3.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↘
Falling
7d Momentum
▼ 1.1%
Volatility
Low
0.0024
Events (7d)
3
Price History
▼16.1%💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF patients with prodromal Parkinson's disease and biomarker evidence of impaired mitochondrial quality control (serumGDF15 >300pg/mL or fibroblast mitophagy flux <40% of age-matched controls) receive | Synaptic density preservation (SV2A PET % change from baseline) in active arm: mean ≥-5% (vs. expected -12% in placebo); CSF NAD+ elevation: mean ≥+40% | — no observation — | pending | 0.45 |
| IF participants with PINK1 or PARK2 mutations (familial PD cohort) are compared to sporadic PD, AD, ALS, and FTD patients matched for disease duration and severity, THEN mitochondrial quality control | MitoScreener score in PINK1/PARK2: median 0.3 (normalized); sporadic PD: 0.6; AD: 0.7; ALS: 0.8; FTD: 0.7 (higher=better function) | — no observation — | pending | 0.55 |
🔮 Falsifiable Predictions (2)
pendingconf 55%
IF participants with PINK1 or PARK2 mutations (familial PD cohort) are compared to sporadic PD, AD, ALS, and FTD patients matched for disease duration and severity, THEN mitochondrial quality control markers in peripheral blood mononuclear cells (MitoScreener assay: ratio of membrane potential to RO
Predicted outcome: MitoScreener score in PINK1/PARK2: median 0.3 (normalized); sporadic PD: 0.6; AD: 0.7; ALS: 0.8; FTD: 0.7 (higher=better function)
Falsification: No significant difference (<20% separation) in mitochondrial quality control scores between PINK1/PARK2 carriers and any other neurodegenerative disease group would indicate mitochondrial dysfunction
pendingconf 45%
IF patients with prodromal Parkinson's disease and biomarker evidence of impaired mitochondrial quality control (serumGDF15 >300pg/mL or fibroblast mitophagy flux <40% of age-matched controls) receive oral nicotinamide riboside 1000mg daily for 52 weeks, THEN their baseline synaptic density (measure
Predicted outcome: Synaptic density preservation (SV2A PET % change from baseline) in active arm: mean ≥-5% (vs. expected -12% in placebo); CSF NAD+ elevation: mean ≥+40
Falsification: SV2A PET decline ≥10% in active arm matching placebo rate, OR <15% NAD+ elevation in CSF, would indicate intervention fails to rescue synaptic vulnerability despite biomarker enrichment.
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.